{
  "id": 12058815,
  "title": "CSL to pay $355M upfront to co-develop Alentis’ kidney and liver drug",
  "url": "https://urgent.news/2026/10/05/csl-to-pay-355m-upfront-to-co-develop-alentis-kidney-and-liver-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-05T02:22:24.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/csl-to-pay-355m-upfront-to-co-develop-alentis-kidney-and-liver-drug/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The Australian drugmaker CSL will pay $355 million for Alentis Therapeutics’ anti-fibrosis drug, plus as much as $1.2 billion in future payments. Under the deal announced Sunday evening, CSL will co-develop ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}